5 Key Takeaways

• 1

  The commentary evaluated a real-world analysis of early selexipag addition to double therapy for pulmonary arterial hypertension.

• 2

  The analysis identified 2,966 eligible patients, with 351 (11.8%) adding oral selexipag to their treatment regimen.

• 3

  Early exposure to selexipag was associated with decreased risk of all-cause hospitalization and PAH-related disease progression.

• 4

  Limitations included missing clinical features for PAH risk assessments and concerns about the accuracy of PAH diagnoses.

• 5

  Despite potential benefits, selexipag was not routinely prescribed and faced higher rates of discontinuation compared to other therapies.